Luvaminos

Semax

A synthetic heptapeptide corresponding to the ACTH(4-7) core sequence with a C-terminal Pro-Gly-Pro extension.

View Semax in the store

Quick answers

What is Semax?

Semax is a synthetic heptapeptide corresponding to the ACTH(4-7) core sequence with a C-terminal Pro-Gly-Pro extension. It is a synthetic peptide (heptapeptide) of 7 amino acids with a molecular weight of 813.93 g/mol and the formula C37H51N9O10S.

How much published research cites Semax?

The Luvaminos Semax record cites 26 published references, dated 1994 to 2022. Each is listed on this page with a link to its source.

Does Luvaminos test Semax, and where is the certificate?

Yes. Every Semax lot Luvaminos sells is tested by Freedom Diagnostics Testing, PLLC, an independent laboratory. The current 5 mg lot, SEMAX-5-001, measured 99.83% purity by HPLC and a net content of 4.37 mg, tested August 8, 2026. Its certificate is published at luvaminos.com/coa/SEMAX-5-001.

What modifications does Semax carry?

Semax: C-terminal Pro-Gly-Pro tripeptide extension of the ACTH(4-7) core; confers resistance to prolyl endopeptidase degradation; PGP is the principal brain metabolite.

How is Semax powder stored?

Sealed Semax powder: -20°C, protected from light and moisture; stable long term. The methionine residue is oxidation-susceptible; protect from light/air; avoid freeze-thaw.

How is Semax different from N-Acetyl Semax?

Semax and N-Acetyl Semax are different compounds: Semax has 7 amino acids, a molecular weight of 813.93 g/mol and formula C37H51N9O10S; N-Acetyl Semax has 7 amino acids, a molecular weight of 855.0 g/mol and formula C39H54N10O10S. Semax: C-terminal Pro-Gly-Pro tripeptide extension of the ACTH(4-7) core. N-Acetyl Semax: N-terminal acetylation and C-terminal amidation of the parent Semax heptapeptide (CAS 80714-61-0).

How is Semax different from Adamax?

Semax and Adamax are different compounds: Semax has 7 amino acids, a molecular weight of 813.93 g/mol and formula C37H51N9O10S; Adamax has 9 amino acids, a molecular weight of 984.10 g/mol and formula C44H61N11O13S. Semax: C-terminal Pro-Gly-Pro tripeptide extension of the ACTH(4-7) core. Adamax: N-terminal acetylation.

How is Semax different from Selank?

Semax and Selank are different compounds: Semax has 7 amino acids, a molecular weight of 813.93 g/mol and formula C37H51N9O10S; Selank has 7 amino acids, a molecular weight of 751.88 g/mol and formula C33H57N11O9. Semax: C-terminal Pro-Gly-Pro tripeptide extension of the ACTH(4-7) core.

Molecular Profile

Type
Synthetic peptide (heptapeptide)
Molecular formula
C37H51N9O10S
Molecular weight
813.93 g/mol
CAS number
80714-61-0
Amino acids
7
Sequence
Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
Modification
C-terminal Pro-Gly-Pro tripeptide extension of the ACTH(4-7) core; confers resistance to prolyl endopeptidase degradation; PGP is the principal brain metabolite.

Mechanism & Target Class

A linear heptapeptide consisting of the ACTH(4-7) core sequence (Met-Glu-His-Phe) extended with a C-terminal Pro-Gly-Pro tripeptide. The Pro-Gly-Pro extension confers resistance to prolyl endopeptidase cleavage relative to the native ACTH(4-10) parent sequence, and the PGP fragment is the predominant brain metabolite identified in distribution studies. In-vitro work has characterized specific, calcium-dependent, reversible binding to a membrane site in rodent brain tissue, consistent with a G-protein-coupled receptor structural context. The methionine residue is oxidation-susceptible, and the histidine and N-terminal residues support copper(II) coordination chemistry studied in neuronal cell models.

Storage & Handling

Lyophilized
-20°C, protected from light and moisture; stable long term.
Handling
The methionine residue is oxidation-susceptible; protect from light/air; avoid freeze-thaw.

Primary Database

PubChem CID 9811102 ↗

References (26)

  1. Reviews

    1

    Dergunova LV, Filippenkov IB, Limborska SA, Myasoedov NF. (2021). Med Res Rev

    DOI: 10.1002/med.21704

  2. 2

    Dergunova LV, et al. (2020). Biochemistry (Moscow)

    DOI: 10.1134/S0006297920030037

  3. 3

    Levitskaya NG, et al. (2018). Biol Bull

    DOI: 10.1134/S1062359018060055

  4. 4

    Tsai SJ. (2007). Medical Hypotheses

    DOI: 10.1016/j.mehy.2006.07.017PubMed 16996699

  5. Clinical

    5

    Gusev EI, et al. (2018). Zh Nevrol Psikhiatr

    DOI: 10.17116/jnevro20181183261-68PubMed 29798983

  6. 6

    Lebedeva IS, et al. (2018). Bull Exp Biol Med

    DOI: 10.1007/s10517-018-4234-3PubMed 30225715

  7. 7

    Kurysheva NI, et al. (2001). Zh Nevrol Psikhiatr

    PubMed 11569188

  8. 8

    Polunin GS, et al. (2000). Vestn Oftalmol

    PubMed 10741256

  9. 9

    Gusev EI, et al. (1997). Zh Nevrol Psikhiatr

    PubMed 11517472

  10. Primary research

    10

    Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F. (2022). ACS Chem Neurosci

    DOI: 10.1021/acschemneuro.1c00707PubMed 35080861

  11. 11

    Sudarkina OY, et al. (2021). Int J Mol Sci

    DOI: 10.3390/ijms22126179PubMed 34201112

  12. 12

    Filippenkov IB, et al. (2020). Genes (Basel)

    DOI: 10.3390/genes11060681PubMed 32580520

  13. 13

    Dergunova LV, Filippenkov IB, et al. (2018). BMC Genomics

    DOI: 10.1186/s12864-018-5039-5

  14. 14

    Medvedeva EV, Dmitrieva VG, et al. (2017). Mol Genet Genomics

    DOI: 10.1007/s00438-017-1297-1

  15. 15

    Medvedeva EV, et al. (2014). BMC Genomics

    DOI: 10.1186/1471-2164-15-228PubMed 24661604

  16. 16

    Manchenko DM, et al. (2012). Neurosci Behav Physiol

    DOI: 10.1007/s11055-012-9562-6

  17. 17

    Agniullin YaV, et al. (2009). J Mol Neurosci

    DOI: 10.1007/s12031-009-9270-zPubMed 19662538

  18. 18

    Shadrina MI, et al. (2007). Neurosci Lett

    PubMed 17353092

  19. 19

    Dolotov OV, et al. (2006). Brain Res

    PubMed 16996037

  20. 20

    Dolotov OV, et al. (2006). J Neurochem

    DOI: 10.1111/j.1471-4159.2006.03658.xPubMed 16635254

  21. 21

    Shevchenko KV, et al. (2006). Russ J Bioorg Chem

    DOI: 10.1134/S1068162006010055PubMed 16523722

  22. 22

    Eremin KO, et al. (2005). Neurochem Res

    DOI: 10.1007/s11064-005-8826-8PubMed 16362768

  23. 23

    Levitskaya NG, et al. (2004). Neurosci Behav Physiol

    DOI: 10.1023/b:neab.0000018752.59465.28PubMed 15341218

  24. 24

    Kost NV, et al. (2001). Russ J Bioorg Chem

    DOI: 10.1023/A:1011373002885

  25. 25

    Bashkatova VG, et al. (2001). Brain Res

    DOI: 10.1016/S0006-8993(00)03324-2PubMed 11245825

  26. 26

    Adan RAH, et al. (1994). Eur J Pharmacol

    PubMed 7895772

Related compounds

Compared side by side

About Semax

What is Semax?

Semax is a synthetic heptapeptide corresponding to the ACTH(4-7) core sequence with a C-terminal Pro-Gly-Pro extension.

What are the molecular formula, molecular weight and CAS number of Semax?

Semax: molecular formula C37H51N9O10S, molecular weight 813.93 g/mol and CAS number 80714-61-0.

What is the sequence of Semax?

Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP).

How is Semax powder stored?

-20°C, protected from light and moisture; stable long term.